MANNKIND CORP (MNKD) Stock Fundamental Analysis
NASDAQ:MNKD - Nasdaq - US56400P7069 - Common Stock - Currency: USD
MNKD gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 555 industry peers in the Biotechnology industry. MNKD has an average financial health and profitability rating. An interesting combination arises when we look at growth and value: MNKD is growing strongly while it also seems undervalued.
1. Profitability
1.1 Basic Checks
In the past year MNKD was profitable.
MNKD had a positive operating cash flow in the past year.
MNKD had negative earnings in 4 of the past 5 years.
In multiple years MNKD reported negative operating cash flow during the last 5 years.
1.2 Ratios
MNKD has a better Return On Assets (7.23%) than 93.15% of its industry peers.
Looking at the Return On Invested Capital, with a value of 22.19%, MNKD belongs to the top of the industry, outperforming 98.02% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.23% | ||
| ROE | N/A | ||
| ROIC | 22.19% |
ROA(3y)-8.37%
ROA(5y)-20.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MNKD's Profit Margin of 9.96% is amongst the best of the industry. MNKD outperforms 92.97% of its industry peers.
Looking at the Operating Margin, with a value of 27.25%, MNKD belongs to the top of the industry, outperforming 97.30% of the companies in the same industry.
Looking at the Gross Margin, with a value of 75.77%, MNKD belongs to the top of the industry, outperforming 83.42% of the companies in the same industry.
In the last couple of years the Gross Margin of MNKD has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.25% | ||
| PM (TTM) | 9.96% | ||
| GM | 75.77% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.44%
GM growth 5Y5.99%
2. Health
2.1 Basic Checks
MNKD has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
MNKD has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, MNKD has more shares outstanding
The debt/assets ratio for MNKD has been reduced compared to a year ago.
2.2 Solvency
MNKD has an Altman-Z score of -7.59. This is a bad value and indicates that MNKD is not financially healthy and even has some risk of bankruptcy.
MNKD has a worse Altman-Z score (-7.59) than 69.37% of its industry peers.
The Debt to FCF ratio of MNKD is 13.30, which is on the high side as it means it would take MNKD, 13.30 years of fcf income to pay off all of its debts.
MNKD has a Debt to FCF ratio of 13.30. This is amongst the best in the industry. MNKD outperforms 91.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 13.3 | ||
| Altman-Z | -7.59 |
ROIC/WACC2.91
WACC7.62%
2.3 Liquidity
A Current Ratio of 2.36 indicates that MNKD has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.36, MNKD is doing worse than 70.99% of the companies in the same industry.
A Quick Ratio of 2.11 indicates that MNKD has no problem at all paying its short term obligations.
MNKD has a worse Quick ratio (2.11) than 72.61% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.36 | ||
| Quick Ratio | 2.11 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 166.67% over the past year.
Looking at the last year, MNKD shows a very strong growth in Revenue. The Revenue has grown by 32.48%.
MNKD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 35.29% yearly.
EPS 1Y (TTM)166.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)32.48%
Revenue growth 3Y55.86%
Revenue growth 5Y35.29%
Sales Q2Q%18.25%
3.2 Future
MNKD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 43.66% yearly.
MNKD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.58% yearly.
EPS Next Y131.63%
EPS Next 2Y81.49%
EPS Next 3Y59.12%
EPS Next 5Y43.66%
Revenue Next Year13.13%
Revenue Next 2Y14.16%
Revenue Next 3Y13.13%
Revenue Next 5Y13.58%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 44.75, which means the current valuation is very expensive for MNKD.
Based on the Price/Earnings ratio, MNKD is valued cheaply inside the industry as 92.25% of the companies are valued more expensively.
MNKD is valuated expensively when we compare the Price/Earnings ratio to 27.21, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 13.59, MNKD is valued correctly.
94.41% of the companies in the same industry are more expensive than MNKD, based on the Price/Forward Earnings ratio.
MNKD is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 21.70, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 44.75 | ||
| Fwd PE | 13.59 |
4.2 Price Multiples
95.86% of the companies in the same industry are more expensive than MNKD, based on the Enterprise Value to EBITDA ratio.
MNKD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. MNKD is cheaper than 92.61% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 49.87 | ||
| EV/EBITDA | 12.05 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as MNKD's earnings are expected to grow with 59.12% in the coming years.
PEG (NY)0.34
PEG (5Y)N/A
EPS Next 2Y81.49%
EPS Next 3Y59.12%
5. Dividend
5.1 Amount
MNKD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
3.58
-0.16 (-4.28%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners58.52%
Inst Owner Change6.07%
Ins Owners1.61%
Ins Owner Change6.24%
Market Cap1.09B
Analysts86.15
Price Target9.62 (168.72%)
Short Float %8.13%
Short Ratio10.19
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-14.59%
Min EPS beat(2)-18.3%
Max EPS beat(2)-10.87%
EPS beat(4)0
Avg EPS beat(4)-77.7%
Min EPS beat(4)-246.98%
Max EPS beat(4)-10.87%
EPS beat(8)3
Avg EPS beat(8)-19.02%
EPS beat(12)5
Avg EPS beat(12)-10.38%
EPS beat(16)6
Avg EPS beat(16)-8.65%
Revenue beat(2)2
Avg Revenue beat(2)0.64%
Min Revenue beat(2)0.38%
Max Revenue beat(2)0.9%
Revenue beat(4)3
Avg Revenue beat(4)0.75%
Min Revenue beat(4)-7.78%
Max Revenue beat(4)9.49%
Revenue beat(8)6
Avg Revenue beat(8)3.43%
Revenue beat(12)9
Avg Revenue beat(12)6.54%
Revenue beat(16)12
Avg Revenue beat(16)6.34%
PT rev (1m)-8.33%
PT rev (3m)-5.71%
EPS NQ rev (1m)11.12%
EPS NQ rev (3m)9.81%
EPS NY rev (1m)0.93%
EPS NY rev (3m)-25.85%
Revenue NQ rev (1m)-1.47%
Revenue NQ rev (3m)-1.73%
Revenue NY rev (1m)-0.56%
Revenue NY rev (3m)-0.82%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 44.75 | ||
| Fwd PE | 13.59 | ||
| P/S | 3.66 | ||
| P/FCF | 49.87 | ||
| P/OCF | 36.97 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 12.05 |
EPS(TTM)0.08
EY2.23%
EPS(NY)0.26
Fwd EY7.36%
FCF(TTM)0.07
FCFY2.01%
OCF(TTM)0.1
OCFY2.7%
SpS0.98
BVpS-0.19
TBVpS-0.22
PEG (NY)0.34
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.23% | ||
| ROE | N/A | ||
| ROCE | 27.56% | ||
| ROIC | 22.19% | ||
| ROICexc | 49.27% | ||
| ROICexgc | 51.75% | ||
| OM | 27.25% | ||
| PM (TTM) | 9.96% | ||
| GM | 75.77% | ||
| FCFM | 7.33% |
ROA(3y)-8.37%
ROA(5y)-20.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.44%
GM growth 5Y5.99%
F-Score7
Asset Turnover0.73
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 13.3 | ||
| Debt/EBITDA | 3 | ||
| Cap/Depr | 93.83% | ||
| Cap/Sales | 2.56% | ||
| Interest Coverage | 5.56 | ||
| Cash Conversion | 33% | ||
| Profit Quality | 73.61% | ||
| Current Ratio | 2.36 | ||
| Quick Ratio | 2.11 | ||
| Altman-Z | -7.59 |
F-Score7
WACC7.62%
ROIC/WACC2.91
Cap/Depr(3y)397.13%
Cap/Depr(5y)337.1%
Cap/Sales(3y)10.78%
Cap/Sales(5y)10.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)166.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y131.63%
EPS Next 2Y81.49%
EPS Next 3Y59.12%
EPS Next 5Y43.66%
Revenue 1Y (TTM)32.48%
Revenue growth 3Y55.86%
Revenue growth 5Y35.29%
Sales Q2Q%18.25%
Revenue Next Year13.13%
Revenue Next 2Y14.16%
Revenue Next 3Y13.13%
Revenue Next 5Y13.58%
EBIT growth 1Y161.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y130.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y148.04%
OCF growth 3YN/A
OCF growth 5YN/A